Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Summary
A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.
Official title: A Phase III, Randomized, Open-Label, Multi-center Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) or TACE Alone in Patients With Incurable Hepatocellular Carcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
423
Start Date
2022-08-09
Completion Date
2026-07-30
Last Updated
2025-12-11
Healthy Volunteers
No
Conditions
Interventions
TACE+Camrelizumab+Apatinib mesylate
TACE. Camrelizumab,200mg,iv,once every 3 weeks. Apatinib mesylate, 250 mg, administered orally once daily,once every 3 weeks.
TACE
TACE Alone.
Locations (1)
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China